title: Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
abstract: Oritavancin possesses activity against vancomycin-resistant enterococci (VRE) and methicillin-resistantStaphylococcus aureus(MRSA).In vitrodata suggest synergy between beta-lactams (BLs) and vancomycin or daptomycin, agents similar to oritavancin. We evaluated the activities of BLs combined with oritavancin against MRSA and VRE. Oritavancin MICs were determined for 30 strains, 5 each of MRSA, daptomycin-nonsusceptible (DNS) MRSA, vancomycin-intermediate MRSA (VISA), heteroresistant VISA (hVISA), vancomycin-resistantEnterococcus faecalis, and vancomycin-resistantEnterococcus faecium Oritavancin MICs were determined in the presence of subinhibitory concentrations of BLs. Oritavancin combined with ceftaroline, cefazolin, or nafcillin was evaluated for lethal synergy against MRSA, and oritavancin combined with ceftaroline, ampicillin, or ertapenem was evaluated for lethal synergy against VRE in 24-h time-kill assays. Oritavancin at 0.5× the MIC was combined with BLs at 0.5× the MIC or the biological free peak concentration, whichever one was lower. Synergy was defined as a ≥2-log10-CFU/ml difference between the killing achieved with the combination and that achieved with the most active single agent at 24 h. Oritavancin MICs were ≤0.125 μg/ml for all MRSA isolates except three VISA isolates with MICs of 0.25 μg/ml. Oritavancin MICs for VRE ranged from 0.03 to 0.125 μg/ml. Oritavancin in combination with ceftaroline was synergistic against all MRSA phenotypes and statistically superior to all other combinations against DNS MRSA, hVISA, and MRSA isolates (P< 0.02). Oritavancin in combination with cefazolin and oritavancin in combination with nafcillin were also synergistic against all MRSA strains. Synergy between oritavancin and all BLs was revealed against VRE strain 8019, while synergy between oritavancin and ampicillin or ertapenem but not ceftaroline was demonstrated against VRE strain R7164. The data support the potential use of oritavancin in combination with BLs, especially oritavancin in combination with ceftaroline, for the treatment of infections caused by MRSA. The data from the present study are not as strong for oritavancin in combination with BLs for VRE. Further study of both MRSA and VRE in more complex models is warranted.
authors.affiliation: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
authors.forename: Jordan R
authors.initials: JR
authors.lastname: Smith
authors.affiliation: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
authors.forename: Juwon
authors.initials: J
authors.lastname: Yim
authors.affiliation: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
authors.forename: Animesh
authors.initials: A
authors.lastname: Raut
authors.affiliation: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA Wayne State University, School of Medicine, Detroit, Michigan, USA aa1592@wayne.edu.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rybak
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002437:Cefazolin / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D017576:Daptomycin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D004357:Drug Synergism; D000077727:Ertapenem; D006020:Glycopeptides / Q000494:pharmacology*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D009254:Nafcillin / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000382:microbiology; D014640:Vancomycin / Q000494:pharmacology / Q000031:analogs & derivatives; D065507:Vancomycin-Resistant Enterococci / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D047090:beta-Lactams / Q000494:pharmacology*; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002437:Cefazolin; D002511:Cephalosporins; D017576:Daptomycin; D000077727:Ertapenem; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D009254:Nafcillin; D014640:Vancomycin; D047090:beta-Lactams; D000097583:Ceftaroline; C100708:oritavancin
references.citation: Clin Infect Dis. 2013 Jun;56(11):1562-9
references.pmid: 23449272
references.citation: Diagn Microbiol Infect Dis. 2011 Dec;71(4):470-3
references.pmid: 22018937
references.citation: Antimicrob Agents Chemother. 2013 Oct;57(10):5005-12
references.pmid: 23896478
references.citation: Antimicrob Agents Chemother. 2013 Dec;57(12):6358-60
references.pmid: 24060866
references.citation: Drug Resist Updat. 2013 Jul-Nov;16(3-5):73-9
references.pmid: 24268586
references.citation: Antimicrob Agents Chemother. 2014;58(2):1028-33
references.pmid: 24277036
references.citation: J Mol Med (Berl). 2014 Feb;92(2):139-49
references.pmid: 24297496
references.citation: Antimicrob Agents Chemother. 2014;58(3):1494-500
references.pmid: 24366742
references.citation: Antimicrob Agents Chemother. 2014 May;58(5):2921-4
references.pmid: 24550323
references.citation: Int J Antimicrob Agents. 2014 May;43(5):465-9
references.pmid: 24636430
references.citation: N Engl J Med. 2014 Jun 5;370(23):2180-90
references.pmid: 24897083
references.citation: Antimicrob Agents Chemother. 2014 Jun;58(6):3177-81
references.pmid: 24663016
references.citation: Antimicrob Agents Chemother. 2014 Oct;58(10):6251-4
references.pmid: 25022588
references.citation: J Antimicrob Chemother. 2014 Nov;69(11):3006-10
references.pmid: 24990867
references.citation: Int J Antimicrob Agents. 2012 Feb;39(2):159-62
references.pmid: 22070858
references.citation: Antimicrob Agents Chemother. 2012 Feb;56(2):838-44
references.pmid: 22123698
references.citation: Antimicrob Agents Chemother. 2012 Mar;56(3):1639-42
references.pmid: 22183169
references.citation: Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9
references.pmid: 22431851
references.citation: Antimicrob Agents Chemother. 2012 Oct;56(10):5296-302
references.pmid: 22869564
references.citation: Antimicrob Agents Chemother. 2012 Nov;56(11):5990-3
references.pmid: 22869580
references.citation: Antimicrob Agents Chemother. 2012 Nov;56(11):5709-14
references.pmid: 22908167
references.citation: Antimicrob Agents Chemother. 2013 Jan;57(1):66-73
references.pmid: 23070161
references.citation: J Antimicrob Chemother. 2013 Mar;68(3):644-7
references.pmid: 23152482
references.citation: Antimicrob Agents Chemother. 2013 May;57(5):2376-9
references.pmid: 23422917
references.citation: Antimicrob Agents Chemother. 2016 Jan;60(1):451-8
references.pmid: 26525797
references.citation: Drugs. 2014 Oct;74(15):1823-8
references.pmid: 25239268
references.citation: Clin Ther. 2014 Oct 1;36(10):1317-33
references.pmid: 25017183
references.citation: Clin Infect Dis. 2015 Jan 15;60(2):254-62
references.pmid: 25294250
references.citation: J Antimicrob Chemother. 2015 Feb;70(2):489-93
references.pmid: 25304643
references.citation: Antimicrob Agents Chemother. 2015 May;59(5):2842-8
references.pmid: 25753639
references.citation: Antimicrob Agents Chemother. 2015;59(6):3365-72
references.pmid: 25824211
references.citation: J Antimicrob Chemother. 2015;70(6):1738-43
references.pmid: 25645208
references.citation: J Antimicrob Chemother. 1996 Mar;37(3):605-9
references.pmid: 9182117
references.citation: Antimicrob Agents Chemother. 2006 Apr;50(4):1581-5
references.pmid: 16569891
references.citation: J Chemother. 2006 Feb;18(1):27-32
references.pmid: 16572890
references.citation: J Biol Chem. 2007 Oct 19;282(42):30414-22
references.pmid: 17646161
references.citation: J Antimicrob Chemother. 2009 Jun;63(6):1191-9
references.pmid: 19369269
references.citation: Mol Microbiol. 2009 May;72(4):895-904
references.pmid: 19400776
references.citation: Clin Infect Dis. 2011 Jul 15;53(2):158-63
references.pmid: 21690622
references.citation: N Engl J Med. 2011 Sep 8;365(10):892-900
references.pmid: 21899450
references.citation: Antimicrob Agents Chemother. 2013 Aug;57(8):4042-5
references.pmid: 23689728